Indefinite Delivery Contract W81K0225DA026
- Not listed
- This indefinite delivery contract was awarded by the Veterans Integrated Service Network 17 (VISN 17) of the U.S. Department of Veterans Affairs to Qiagen, LLC, a division of the international medical diagnostics provider Qiagen N.V. The contract is for the supply of QuantiFERON-TB Gold Plus (QFT-Plus) reagents, which are used for latent tuberculosis infection testing. The base contract has a firm fixed price of $106,687.50 and a period of performance through November 30, 2025. This is a task...
- This federal contract IDV was awarded by the Defense Health Agency (DHA), a defense agency, to Qiagen, LLC, a subsidiary of the international diagnostics company Qiagen N.V. The $391,649 single-award indefinite delivery contract, with a period of performance through September 2025, aims to provide the DHA with QFT reagents and controls to support tuberculosis testing programs at military treatment facilities. Under this IDV, DHA has issued multiple delivery orders to Qiagen for the provision...
- Qiagen, LLC was awarded a single-award Blanket Purchase Agreement valued at $5.12 million by Veterans Integrated Service Network 22 (VISN 22), a component of the Department of Veterans Affairs, on December 9, 2024, for the procurement of tuberculosis testing reagents. The contract extends through December 8, 2026, and was issued without a set-aside designation, indicating open competition. The underlying solicitation, posted November 14, 2024, specified a requirement for Food and Drug...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 9 awarded an indefinite delivery contract to Qiagen, LLC, a division of Qiagen N.V., to provide QuantiFERON TB Gold Plus reagents and supplies for tuberculosis testing at the Serological Reference Laboratory in Lexington, Kentucky and other VA locations. The $942,007.26 contract has a period of performance through September 30, 2024 and does not include any set-aside designations....
- This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA), Veterans Integrated Service Network 15 (VISN 15) to Qiagen, LLC, a foreign-owned, for-profit manufacturer of molecular diagnostics, scientific equipment, and bioinformatics solutions. The contract, valued at a ceiling of $367,001.40, is for the supply of QuantiFERON (QFT) TB Gold Plus testing kits and related supplies to support the St. Louis VA Medical Center. The period of performance spans...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a single award indefinite delivery/indefinite quantity contract to Qiagen, LLC to supply Quantiferon tests and associated materials. The contract established a potential value of $900,000 over a five year period of performance from August 2021 to August 2026 to support tuberculosis screening programs. Against this contract vehicle, the agency issued four delivery orders to Qiagen...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 awarded a blanket purchase agreement to Qiagen, LLC for the provision of Quantiferon reagents, test kits, and supplies for tuberculosis testing. The single award blanket purchase agreement has a potential value of $315,600 and a period of performance from April 19, 2021 through April 18, 2026. Two firm fixed price calls were placed against the agreement for reagents, test kits, and...
- This federal contract Indefinite Delivery Vehicle (IDV) is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 19 (VISN 19) to Qiagen, LLC, a subsidiary of the multinational biotechnology company Qiagen N.V. The contract, valued at $420,525.00, provides for the ordering of QuantiFERON reagents, which are used for tuberculosis testing, over a period of approximately 4 years from September 1, 2024 to August 31, 2028. The...
- This federal Blanket Purchase Agreement (BPA) was awarded by the Defense Health Agency (DHA), a component of the U.S. Department of Defense, to Qiagen, LLC, a foreign-owned, for-profit manufacturer of molecular diagnostics and genomic testing solutions. The single-award BPA has a ceiling value of $7,433,000 and a period of performance through October 2028. Under this BPA, Qiagen will provide a range of reagents, consumables, laboratory equipment, and bioinformatics software to support DHA's...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a single-award Indefinite Delivery Contract (IDC) to Government Scientific Source Inc. (GSS), a for-profit organization, for the provision of QUANTIFERON-TB GOLD PLUS diagnostic tests. The contract has a ceiling value of $380,460.00 and a period of performance from May 23, 2024 to May 22, 2026. Under this IDC, the VA issued a $76,092.00 firm fixed price delivery order for QUANTIFERON TB ELISA KIT, with a completion...
- W81K0225DA026Indefinite Delivery Contract
- 1Federal Contract Awards
Qiagen, LLC has been awarded a single-award Indefinite Delivery Contract valued at $489,895.00 by the Defense Health Agency to supply QuantiFERON TB Gold-Plus assays, reagents, and controls for the detection of Mycobacterium tuberculosis. The contract, awarded November 1, 2025, extends through September 30, 2030, and supports the Department of Defense's medical readiness initiatives. The initial task order, issued October 1, 2025, carries a ceiling value of $97,179.00 with an ultimate completion date of September 30, 2026, and specifies firm fixed pricing for delivery from Qiagen's Germantown, Maryland facility. This procurement addresses the Defense Health Agency's requirement for FDA-approved latent tuberculosis testing capabilities utilizing Interferon Gamma Release technology, which Qiagen currently supplies as the only approved source for in-house latent TB detection from blood samples using this methodology. The underlying market research, conducted by the Medical Readiness Contracting Office—Pacific at Joint Base Lewis McChord, identified the specialized diagnostic needs of Madigan Army Medical Center's Department of Pathology for tuberculosis detection reagents compatible with their existing LIAISON XL System instrumentation. The pre-solicitation notice, posted August 21, 2025, indicated that the government sought to determine appropriate acquisition methods while recognizing Qiagen's incumbent position and unique FDA approval status for this diagnostic assay. The absence of set-aside designations reflects the specialized technical requirements and limited competitive sources available for this critical medical readiness application, positioning this contract as essential infrastructure for tuberculosis screening across Department of Defense medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $0 | 9/17/25 |
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
Delivery Order W81K0225DA026-W81K0225FA153 | Qiagen, LLC | $97.2k | 10/1/25 | 9/30/26 | 9/17/25 |
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus | W81K0225QA107 | Department of the Army Medical Command | Solicitation 2/3 | 9/16/25, 1:01 PM | |
Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus | W81K0225QA100 | Department of the Army Medical Command | Pre-Solicitation 1/3 | 8/21/25, 6:11 PM | |
Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus | W81K0225DA026 | Department of the Army Medical Command | Award Notice 3/3 | 9/17/25, 3:45 PM |